Ad
related to: immunogen
Search results
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
Zacks via Yahoo Finance· 2 years agoImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat...
ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues
Zacks via Yahoo Finance· 7 months agoImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong...
ImmunoGen (IMGN) Q1 Earnings Beat, Elahere Uptake Encouraging
Zacks via Yahoo Finance· 1 year agoImmunoGen (IMGN) reports impressive Q1 earnings results on strong adoption of sole-marketed drug...
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug
Zacks via Yahoo Finance· 2 years agoImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx,...
ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline
Zacks via Yahoo Finance· 2 years agoImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop...
ImmunoGen (IMGN) Reports Q3 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 2 years agoImmunoGen (IMGN) delivered earnings and revenue surprises of -19.23% and 30.16%, respectively, for...
ImmunoGen (IMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Zacks via Yahoo Finance· 10 months agoImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings...
ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why
Zacks via Yahoo Finance· 1 year agoImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the...
ImmunoGen Allows Vertex Pharma Use Its Technology For Conditioning Agents For Use With Gene Editing
Benzinga via Yahoo Finance· 1 year agoImmunoGen Inc (NASDAQ: IMGN) announced a global, multi-target license and option agreement that...
With 72% institutional ownership, ImmunoGen, Inc. (NASDAQ:IMGN) is a favorite amongst the big guns
Simply Wall St. via Yahoo Finance· 1 year agoEvery investor in ImmunoGen, Inc. (NASDAQ:IMGN) should be aware of the most powerful shareholder...